Researcher profile

James D. Brooks

James D. Brooks contributes to research discovery and scholarly infrastructure.

ResearcherAffiliation not importedOpen to collaborate

Trust snapshot

Quick read

Trust 13 - UnverifiedVerification L1Unclaimed author
2works
0followers
5topics
4close collaborators

Actions

Decide how to stay connected

Follow researcher0

Identity and collaboration

How to connect with this researcher

Claiming links this public author record to a researcher profile and unlocks direct collaboration workflows.

Log in to claim

Direct collaboration

Open a focused conversation when the fit is right

Claim this author entity first to unlock direct invitations.

Research graph

See the researcher in context

Open full explorer

Inspect adjacent work, topics, institutions and collaborators without jumping out to a separate graph page.

Building this graph slice

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

2 published item(s)

preprint2020arXiv

CorrSigNet: Learning CORRelated Prostate Cancer SIGnatures from Radiology and Pathology Images for Improved Computer Aided Diagnosis

Magnetic Resonance Imaging (MRI) is widely used for screening and staging prostate cancer. However, many prostate cancers have subtle features which are not easily identifiable on MRI, resulting in missed diagnoses and alarming variability in radiologist interpretation. Machine learning models have been developed in an effort to improve cancer identification, but current models localize cancer using MRI-derived features, while failing to consider the disease pathology characteristics observed on resected tissue. In this paper, we propose CorrSigNet, an automated two-step model that localizes prostate cancer on MRI by capturing the pathology features of cancer. First, the model learns MRI signatures of cancer that are correlated with corresponding histopathology features using Common Representation Learning. Second, the model uses the learned correlated MRI features to train a Convolutional Neural Network to localize prostate cancer. The histopathology images are used only in the first step to learn the correlated features. Once learned, these correlated features can be extracted from MRI of new patients (without histopathology or surgery) to localize cancer. We trained and validated our framework on a unique dataset of 75 patients with 806 slices who underwent MRI followed by prostatectomy surgery. We tested our method on an independent test set of 20 prostatectomy patients (139 slices, 24 cancerous lesions, 1.12M pixels) and achieved a per-pixel sensitivity of 0.81, specificity of 0.71, AUC of 0.86 and a per-lesion AUC of $0.96 \pm 0.07$, outperforming the current state-of-the-art accuracy in predicting prostate cancer using MRI.

preprint2020arXiv

Plexus Convolutional Neural Network (PlexusNet): A novel neural network architecture for histologic image analysis

Different convolutional neural network (CNN) models have been tested for their application in histological image analyses. However, these models are prone to overfitting due to their large parameter capacity, requiring more data or valuable computational resources for model training. Given these limitations, we introduced a novel architecture (termed PlexusNet). We utilized 310 Hematoxylin and Eosin stained (H&E) annotated histological images of prostate cancer cases from TCGA-PRAD and Stanford University and 398 H&E whole slides images from the Camelyon 2016 challenge. PlexusNet-architecture -derived models were compared to models derived from several existing "state of the art" architectures. We measured discrimination accuracy, calibration, and clinical utility. An ablation study was conducted to study the effect of each component of PlexusNet on model performance. A well-fitted PlexusNet-based model delivered comparable classification performance (AUC: 0.963) in distinguishing prostate cancer from healthy tissues, although it was at least 23 times smaller, had a better model calibration and clinical utility than the comparison models. A separate smaller PlexusNet model accurately detected slides with breast cancer metastases (AUC: 0.978); it helped reduce the slide number to examine by 43.8% without consequences, although its parameter capacity was 200 times smaller than ResNet18. We found that the partitioning of the development set influences the model calibration for all models. However, with PlexusNet architecture, we could achieve comparable well-calibrated models trained on different partitions. In conclusion, PlexusNet represents a novel model architecture for histological image analysis that achieves classification performance comparable to other models while providing orders-of-magnitude parameter reduction.